Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, multicentre, randomised, controlled, double-blind, non-inferiority trial.
Saved in:
| Title: | Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, multicentre, randomised, controlled, double-blind, non-inferiority trial. |
|---|---|
| Authors: | Colson AE; Community Resource Initiative, Boston, MA, USA; Cambridge Health Alliance, Cambridge, MA, USA., Mills AM; Men's Health Foundation, Los Angeles, CA, USA., Ramgopal MN; Midway Immunology and Research Center, Fort Pierce, FL, USA., Bettacchi C; HIV Center, North Texas Infectious Diseases Consultants, Dallas, TX, USA., Osiyemi OO; Triple O Research Institute, West Palm Beach, FL, USA., Hinestrosa F; Orlando Immunology Center, Orlando, FL, USA., Crofoot G; The Crofoot Research Center, Houston, TX, USA., Katner HP; Mercer University School of Medicine, Macon, GA, USA., Gatanaga H; AIDS Clinical Center, NCGM, Tokyo, Japan., Johnson M; Royal Free London NHS Foundation Trust, London, UK., Diamond TL; Merck & Co, Rahway, NJ, USA., Barninger E; Merck & Co, Rahway, NJ, USA., Eves K; Merck & Co, Rahway, NJ, USA., Su FH; Merck & Co, Rahway, NJ, USA., Xu Y; Merck & Co, Rahway, NJ, USA., Klopfer SO; Merck & Co, Rahway, NJ, USA., Stamm LM; Merck & Co, Rahway, NJ, USA., Fox MC; Merck & Co, Rahway, NJ, USA., Lahoulou R; Merck & Co, Rahway, NJ, USA. Electronic address: rima.lahoulou@merck.com. |
| Source: | Lancet (London, England) [Lancet] 2026 Feb 07; Vol. 407 (10528), pp. 611-621. |
| Publication Type: | Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study; Equivalence Trial |
| Journal Info: | Publisher: Elsevier Country of Publication: England NLM ID: 2985213R Publication Model: Print Cited Medium: Internet ISSN: 1474-547X (Electronic) Linking ISSN: 01406736 NLM ISO Abbreviation: Lancet Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 41654375 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, multicentre, randomised, controlled, double-blind, non-inferiority trial. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Colson+AE%22">Colson AE</searchLink>; Community Resource Initiative, Boston, MA, USA; Cambridge Health Alliance, Cambridge, MA, USA.<br /><searchLink fieldCode="AU" term="%22Mills+AM%22">Mills AM</searchLink>; Men's Health Foundation, Los Angeles, CA, USA.<br /><searchLink fieldCode="AU" term="%22Ramgopal+MN%22">Ramgopal MN</searchLink>; Midway Immunology and Research Center, Fort Pierce, FL, USA.<br /><searchLink fieldCode="AU" term="%22Bettacchi+C%22">Bettacchi C</searchLink>; HIV Center, North Texas Infectious Diseases Consultants, Dallas, TX, USA.<br /><searchLink fieldCode="AU" term="%22Osiyemi+OO%22">Osiyemi OO</searchLink>; Triple O Research Institute, West Palm Beach, FL, USA.<br /><searchLink fieldCode="AU" term="%22Hinestrosa+F%22">Hinestrosa F</searchLink>; Orlando Immunology Center, Orlando, FL, USA.<br /><searchLink fieldCode="AU" term="%22Crofoot+G%22">Crofoot G</searchLink>; The Crofoot Research Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Katner+HP%22">Katner HP</searchLink>; Mercer University School of Medicine, Macon, GA, USA.<br /><searchLink fieldCode="AU" term="%22Gatanaga+H%22">Gatanaga H</searchLink>; AIDS Clinical Center, NCGM, Tokyo, Japan.<br /><searchLink fieldCode="AU" term="%22Johnson+M%22">Johnson M</searchLink>; Royal Free London NHS Foundation Trust, London, UK.<br /><searchLink fieldCode="AU" term="%22Diamond+TL%22">Diamond TL</searchLink>; Merck & Co, Rahway, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Barninger+E%22">Barninger E</searchLink>; Merck & Co, Rahway, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Eves+K%22">Eves K</searchLink>; Merck & Co, Rahway, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Su+FH%22">Su FH</searchLink>; Merck & Co, Rahway, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Xu+Y%22">Xu Y</searchLink>; Merck & Co, Rahway, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Klopfer+SO%22">Klopfer SO</searchLink>; Merck & Co, Rahway, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Stamm+LM%22">Stamm LM</searchLink>; Merck & Co, Rahway, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Fox+MC%22">Fox MC</searchLink>; Merck & Co, Rahway, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Lahoulou+R%22">Lahoulou R</searchLink>; Merck & Co, Rahway, NJ, USA. Electronic address: rima.lahoulou@merck.com. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%222985213R%22">Lancet (London, England)</searchLink> [Lancet] 2026 Feb 07; Vol. 407 (10528), pp. 611-621. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study; Equivalence Trial – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier%22">Elsevier </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>2985213R <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1474-547X (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2201406736%22">01406736 </searchLink><i>NLM ISO Abbreviation: </i>Lancet <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41654375 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/S0140-6736(25)01948-8 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 611 Titles: – TitleFull: Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, multicentre, randomised, controlled, double-blind, non-inferiority trial. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Colson AE – PersonEntity: Name: NameFull: Mills AM – PersonEntity: Name: NameFull: Ramgopal MN – PersonEntity: Name: NameFull: Bettacchi C – PersonEntity: Name: NameFull: Osiyemi OO – PersonEntity: Name: NameFull: Hinestrosa F – PersonEntity: Name: NameFull: Crofoot G – PersonEntity: Name: NameFull: Katner HP – PersonEntity: Name: NameFull: Gatanaga H – PersonEntity: Name: NameFull: Johnson M – PersonEntity: Name: NameFull: Diamond TL – PersonEntity: Name: NameFull: Barninger E – PersonEntity: Name: NameFull: Eves K – PersonEntity: Name: NameFull: Su FH – PersonEntity: Name: NameFull: Xu Y – PersonEntity: Name: NameFull: Klopfer SO – PersonEntity: Name: NameFull: Stamm LM – PersonEntity: Name: NameFull: Fox MC – PersonEntity: Name: NameFull: Lahoulou R IsPartOfRelationships: – BibEntity: Dates: – D: 07 M: 02 Text: 2026 Feb 07 Type: published Y: 2026 Identifiers: – Type: issn-electronic Value: 1474-547X Numbering: – Type: volume Value: 407 – Type: issue Value: 10528 Titles: – TitleFull: Lancet (London, England) Type: main |
| ResultId | 1 |
